PT  - JOURNAL ARTICLE
AU  - May, Damon H.
AU  - Rubin, Benjamin E. R.
AU  - Dalai, Sudeb C.
AU  - Patel, Krishna
AU  - Shafiani, Shahin
AU  - Elyanow, Rebecca
AU  - Noakes, Matthew T.
AU  - Snyder, Thomas M.
AU  - Robins, Harlan S.
TI  - Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccines
AID  - 10.1101/2021.12.20.21267877
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.20.21267877
4099  - http://medrxiv.org/content/early/2021/12/27/2021.12.20.21267877.short
4100  - http://medrxiv.org/content/early/2021/12/27/2021.12.20.21267877.full
AB  - The Omicron SARS-CoV-2 variant contains 34 mutations in the spike gene likely impacting protective efficacy from vaccines. We evaluated the potential impact of these mutations on the cellular immune response. Combining epitope mapping to SARS-CoV-2 vaccines that we have determined from past experiments along with T cell receptor (TCR) repertoire sequencing from thousands of vaccinated or naturally infected individuals, we estimate the abrogation of the cellular immune response in Omicron. Although 20% of CD4+ T cell epitopes are potentially affected, the loss of immunity mediated by CD4+ T cells is estimated to be slightly above 30% as some of the affected epitopes are relatively more immunogenic. For CD8+ T cells, we estimate a loss of approximately 20%. These reductions in T cell immunity are substantially larger than observed in other widely distributed variants. Combined with the expected substantial loss of neutralization from antibodies, the overall protection provided by SARS-CoV-2 vaccines could be impacted adversely. From analysis of prior variants, the efficacy of vaccines against symptomatic infection has been largely maintained and is strongly correlated with the T cell response but not as strongly with the neutralizing antibody response. We expect the remaining 70% to 80% of on-target T cells induced by SARS-CoV-2 vaccination to reduce morbidity and mortality from infection with Omicron.Competing Interest StatementAll authors declare employment and equity interest with Adaptive Biotechnologies. Additionally, SCD declares employment with Stanford University School of Medicine; and HSR also declares leadership with Adaptive Biotechnologies.Funding StatementThis study was funded by Adaptive Biotechnologies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data analyzed in this study were derived from samples that had been acquired and sequenced previously. The data source included a public database (GSAID) for which no IRB approval is necessary. The MIRA data were from the ImmuneRACE study33, Bloodworks NW (Seattle, WA), and Discovery Life Sciences (DLS) commercial vendor. The ImmuneRACE study was approved by Western Institutional Review Board (WIRB reference number 1-1281891-1, Protocol ADAP-006). Bloodworks NW donor samples had been consented and collected under the Bloodworks Research Donor Collection Protocol BT001, while the DLS samples had been collected under Protocol DLS13.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs part of the ImmuneCODE data resource, the COVID-19 MIRA data and COVID-19 study immunosequencing data are freely available for analysis and download from the Adaptive Biotechnologies immuneACCESS site under the immuneACCESS Terms of Use at https://clients.adaptivebiotech.com/pub/covid-2020. This resource is being updated with the additional vaccine repertoire and other data included in this analysis. https://clients.adaptivebiotech.com/pub/covid-2020